Medico Remedies Ltd (MEDICO) — shareholding pattern, promoter holding, financials and share price
About Medico Remedies Ltd (MEDICO)
Medico Remedies Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as MEDICO and on the BSE under scrip code 540937. Its ISIN is INE630Y01024.
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations [1]
Medico Remedies Limited is a pharmaceutical company specializing in manufacturing and marketing pharmaceutical formulations. Their expertise includes anti-infective, antimalarial, and cardiovascular drugs among other categories.
The company's manufacturing facilities are ISO 9001:2015 certified and have WHO-GMP accreditation, indicating high quality and compliance with international standards.
Listed peers in Pharmaceuticals: Valiant Laboratories Ltd, Medicamen Biotech Ltd, Infinium Pharmachem Ltd, Trident Lifeline Ltd, Everest Organics Ltd, BDH Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹39.62 a share on 10 Jul 2026, Medico Remedies Ltd (MEDICO) was valued at a price-to-earnings ratio of 25.06x against an industry P/E of 36.41x and a price-to-book of 5.26x on a book value of ₹7.53 per share as of Mar 2025. Solomo computes return on equity of 21% and return on capital employed of 25.74% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 25.06x
- Industry P/E
- 36.41x
- P/B
- 5.26x
- EPS (TTM)
- ₹1.58
- Book value / share
- ₹7.53
- ROE
- 21%
- ROCE
- 25.74%
- ROA
- 10.95%
- Debt / equity
- 0.24x
- Dividend yield
- 0%
- EBITDA margin
- 11.12%
- 52-week range
- ₹31 – ₹56.99
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Medico Remedies Ltd (MEDICO) reported revenue of ₹206 crore, net profit of ₹13 crore and earnings per share of ₹1.58. That compares with revenue of ₹151 crore and net profit of ₹10 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹56.81 crore and net profit ₹5.86 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 121 | 140 | 145 | 151 | 206 |
| Net profit (₹ cr) | 5 | 7 | 8 | 10 | 13 |
| EPS (₹) | 0.58 | 0.87 | 1 | 1.22 | 1.58 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 8.84% | 11.23% | 7.64% | 4.15% |
| Profit growth | 27.55% | 44.00% | 28.01% | 21.71% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 61.38% of Medico Remedies Ltd (MEDICO) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.08%. Market capitalisation was ₹329 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2018.
Largest disclosed public shareholders in Jun 2026: RAVI GOYAL 6.83%, HUF 1.9%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 61.38% | - | 0.08% | - | 38.62% |
| Mar 2026 | 61.38% | - | 0.03% | - | 38.62% |
| Dec 2025 | 61.38% | - | 0.49% | - | 38.62% |
| Sep 2025 | 61.38% | - | 0.3% | 0.01% | 38.62% |
| Jun 2025 | 62.59% | - | 0.07% | 0.01% | 37.41% |
| Mar 2025 | 63.79% | - | 0.12% | 0.01% | 36.21% |
| Dec 2024 | 66.83% | - | 0.39% | 0.78% | 33.17% |
| Sep 2024 | 73.34% | - | 0.22% | 0.97% | 26.66% |